南微医学
(688029)
| 流通市值：136.49亿 | | | 总市值：136.49亿 |
| 流通股本：1.88亿 | | | 总股本：1.88亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 620,078,643.58 | 2,411,468,385.36 | 1,745,324,768.57 | 1,147,134,950.13 |
| 营业收入 | 620,078,643.58 | 2,411,468,385.36 | 1,745,324,768.57 | 1,147,134,950.13 |
| 二、营业总成本 | 447,485,577.57 | 1,854,314,053.6 | 1,293,258,893.85 | 827,845,546.38 |
| 营业成本 | 196,484,985.91 | 855,981,926.49 | 627,541,330.49 | 415,919,744.35 |
| 税金及附加 | 6,128,792.57 | 24,094,398.56 | 17,257,553.58 | 10,618,120.86 |
| 销售费用 | 134,457,580.03 | 572,528,707.7 | 382,701,595.11 | 252,928,133.6 |
| 管理费用 | 82,485,457.06 | 328,738,169.12 | 226,303,203.75 | 152,305,038.41 |
| 研发费用 | 30,920,136.25 | 150,803,264.76 | 102,602,589.38 | 68,673,434.23 |
| 财务费用 | -2,991,374.25 | -77,832,413.03 | -63,147,378.46 | -72,598,925.07 |
| 其中:利息费用 | 760,922.45 | 2,041,048.83 | 528,452.81 | 264,474.16 |
| 其中:利息收入 | 15,689,602.29 | 49,927,116.29 | 35,321,960.55 | 21,061,322.42 |
| 加:公允价值变动收益 | 1,276,235.99 | 15,881.06 | 2,306,266.65 | 143,184.74 |
| 加:投资收益 | 2,803,690.3 | 27,824,812.68 | 18,974,195.81 | 14,325,060.54 |
| 资产处置收益 | - | 60,473.02 | 31,084.12 | 31,084.12 |
| 资产减值损失(新) | -4,246,855.29 | -34,641,137.34 | -14,867,047.24 | -10,365,947 |
| 信用减值损失(新) | -873,401.52 | -1,056,116.53 | -1,577,397.65 | -7,061,869.89 |
| 其他收益 | 1,406,290.65 | 5,310,900.83 | 883,346.71 | 883,346.71 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 172,959,026.14 | 554,669,145.48 | 457,816,323.12 | 317,244,262.97 |
| 加:营业外收入 | 768,275.76 | 17,183,039.51 | 2,676,154.59 | 1,483,410.71 |
| 减:营业外支出 | 18,781.12 | 6,942,267.37 | 5,132,763.02 | 4,581,632.8 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 173,708,520.78 | 564,909,917.62 | 455,359,714.69 | 314,146,040.88 |
| 减:所得税费用 | 26,253,742.04 | 70,209,366.1 | 60,283,033.24 | 43,131,236.05 |
| 六、净利润 | 147,454,778.74 | 494,700,551.52 | 395,076,681.45 | 271,014,804.83 |
| 持续经营净利润 | 147,454,778.74 | 494,700,551.52 | 395,076,681.45 | 271,014,804.83 |
| 归属于母公司股东的净利润 | 143,464,442.08 | 485,924,270.19 | 386,526,300.88 | 264,298,343.65 |
| 少数股东损益 | 3,990,336.66 | 8,776,281.33 | 8,550,380.57 | 6,716,461.18 |
| (一)基本每股收益 | 0.76 | 2.59 | 2.06 | 1.41 |
| (二)稀释每股收益 | 0.76 | 2.59 | 2.06 | 1.41 |
| 八、其他综合收益 | -4,059,448.59 | 2,085,032.26 | 923,703.61 | 7,952,454.34 |
| 归属于母公司股东的其他综合收益 | -4,059,158.44 | 2,087,736.51 | 928,649.44 | 7,958,446.66 |
| 九、综合收益总额 | 143,395,330.15 | 496,785,583.78 | 396,000,385.06 | 278,967,259.17 |
| 归属于母公司股东的综合收益总额 | 139,405,283.64 | 488,012,006.7 | 387,454,950.32 | 272,256,790.31 |
| 归属于少数股东的综合收益总额 | 3,990,046.51 | 8,773,577.08 | 8,545,434.74 | 6,710,468.86 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-28 | 2023-08-08 |
| 审计意见(境内) | | 标准无保留意见 | | |